Theranostics
2017; 7(7):2111-2133.
doi:10.7150/thno.17934 This issueCite
Review
Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine
Martin Pool1*, H. Rudolf de Boer1*, Marjolijn N. Lub-de Hooge2, 3, Marcel A.T.M. van Vugt1#✉, Elisabeth G.E. de Vries1#✉
1. Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 2. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 3. Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. * Co-first author # Co-senior author
✉ Corresponding authors: Elisabeth G.E. de Vries, MD, PhD, Marcel A.T.M. van Vugt, PhD, Department of Medical Oncology, University of Groningen, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands +31 50 3612934 (EGEdV) / +31 50 3615002 (MATMvV) e.ge.de.vriesnl / m.vugtnlMore
Citation:
Pool M, de Boer HR, Hooge MNLd, van Vugt MATM, de Vries EGE. Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine. Theranostics 2017; 7(7):2111-2133. doi:10.7150/thno.17934. https://www.thno.org/v07p2111.htm
Cancer is a growing problem worldwide. The cause of death in cancer patients is often due to treatment-resistant metastatic disease. Many molecularly targeted anticancer drugs have been developed against 'oncogenic driver' pathways. However, these treatments are usually only effective in properly selected patients. Resistance to molecularly targeted drugs through selective pressure on acquired mutations or molecular rewiring can hinder their effectiveness. This review summarizes how molecular imaging techniques can potentially facilitate the optimal implementation of targeted agents. Using the human epidermal growth factor receptor (HER) family as a model in (pre)clinical studies, we illustrate how molecular imaging may be employed to characterize whole body target expression as well as monitor drug effectiveness and the emergence of tumor resistance. We further discuss how an integrative omics discovery platform could guide the selection of 'effect sensors' - new molecular imaging targets - which are dynamic markers that indicate treatment effectiveness or resistance.
Keywords: Molecular imaging, cancer therapy, personalized medicine, EGFR, HER2, HER3, drug resistance.
Citation styles
APA
Pool, M., de Boer, H.R., Hooge, M.N.L.d., van Vugt, M.A.T.M., de Vries, E.G.E. (2017). Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine. Theranostics, 7(7), 2111-2133. https://doi.org/10.7150/thno.17934.
ACS
Pool, M.; de Boer, H.R.; Hooge, M.N.L.d.; van Vugt, M.A.T.M.; de Vries, E.G.E. Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine. Theranostics 2017, 7 (7), 2111-2133. DOI: 10.7150/thno.17934.
NLM
Pool M, de Boer HR, Hooge MNLd, van Vugt MATM, de Vries EGE. Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine. Theranostics 2017; 7(7):2111-2133. doi:10.7150/thno.17934. https://www.thno.org/v07p2111.htm
CSE
Pool M, de Boer HR, Hooge MNLd, van Vugt MATM, de Vries EGE. 2017. Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine. Theranostics. 7(7):2111-2133.
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.